MedTrace Logo

Effects of Modafinil on Brain Function in Patients With Schizophrenia

NCT00057707 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 176

Last updated 2019-12-09

No results posted yet for this study

Summary

This study will evaluate whether modafinil improves cognition in patients with schizophrenia and healthy volunteers. Modafinil is a drug that has been FDA approved for day-time sleepiness and allegedly increase the amount of the neurotransmitter dopamine in the frontal cortex of the brain

...

Conditions

Interventions

DRUG

Modafinil

Placebo 1 week-Wash out 1 week - Drug 1 week (or vice versa)

PROCEDURE

Functional MRI

PROCEDURE

Neuropsychological Testing

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    lead NIH

Principal Investigators

  • Jose A Apud, M.D. · National Institute of Mental Health (NIMH)

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-03-26
Primary Completion
2017-06-16
Completion
2017-06-16

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00057707 on ClinicalTrials.gov